Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
50 hedge funds and large institutions have $32.4M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 10 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
2% more funds holding
Funds holding: 49 → 50 (+1)
54% less capital invested
Capital invested by funds: $71.1M → $32.4M (-$38.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$1.31M |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$380K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$354K |
| 4 |
Renaissance Technologies
New York
|
+$301K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$178K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
-$2.16M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.03M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$758K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$701K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$580K |
DRNA Hedge Fund Activity: Q4 2016 in Review
50 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q4 2016, worth a combined $32.4M — down 54% from $71.1M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DRNA positions and 10 closed out — a net gain of 1 holder — while 16 added to existing stakes and 13 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $1.31M. The largest seller was Abingworth, cutting an estimated $2.16M.
- 50 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q4 2016, up from 49 in Q3 2016.
- Funds reported $32.4M of Dicerna Pharmaceuticals, Inc. stock for Q4 2016, down 54% quarter-over-quarter.
- 11 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q4 2016 and 10 closed out, a net change of +1 holder.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q4 2016 was 683 Capital Management, an estimated $1.31M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q4 2016 was Abingworth, an estimated $2.16M sold.
Based on aggregated 13F filings for Q4 2016.